In the world of medical cannabis, creating the best medicines has become quite a competition, leading companies to create novel technologies to do so. This is the case with Cannabics Pharmaceuticals, which just won a patent through the European Patent Office, for its new cancer drug discovery technology.Of course, Cannabics is up to way more than that.
Medical cannabis has come a long way. From Cannabics Pharmaceuticals and its new-age cannabis cancer treatments, to delta-8 THC – an alternative to delta-9, which won’t cause anxiety, and leaves users with a clear-headed high, and slightly less psychoactive effect.New cannabis technology means new and improved products for consumers, and that’s good for you. If you want to try what today’s world of cannabis technology has to offer, check out our array of Delta-8 THCdeals, and take advantage of today’s best advancements in cannabis products.
What is Cannabics Pharmaceuticals?
Cannabics Pharmaceuticals is a publicly traded pharmaceutical company that specializes in cannabis treatments for cancer. The company is based out of the US, with its research & development team in Rehovot, Israel. In Israel, Cannabics Pharmaceuticals has licensing through the Ministry of Health to perform research on cannabis medications for use with cancer specifically.
The company was formed in 2012 in Bethesda, Maryland. It is publicly traded under (CNBX: OTCQB). As a small pharma company it only has 11-50 employees according to its LinkedIn page. In October of 2020, Cannabics Pharmaceuticals received an ‘Intention to Grant a European Patent’, from the European Patent Office (EPO), for a patent related to cancer-screening medication development.
Patent approval
It was announced on May 25th, that Cannabics Pharmaceuticals had been granted a patent for its drug discovery technology that works on a personalized level for patients. The patent is entitled, System and Method for High Throughput Screening of Cancer Cells. According to Cannabics Pharmaceutical’s co-founder and CTO Eyal Ballan: